Literature DB >> 21999595

mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.

Charles H C Pilgrim1, Kate Brettingham-Moore, Alan Pham, William Murray, Emma Link, Marty Smith, Val Usatoff, Peter M Evans, Simon Banting, Benjamin N Thomson, Michael Michael, Wayne A Phillips.   

Abstract

INTRODUCTION: Chemotherapy-induced hepatic injuries (CIHI) are an increasing problem facing hepatic surgeons. It may be possible to predict the risk of developing CIHI by analysis of genes involved in the metabolism of chemotherapeutics, previously established as associated with other forms of toxicity.
METHODS: Quantitative reverse transcriptase-polymerase chain reaction methodology (q-RT-PCR) was employed to quantify mRNA expression of nucleotide excision repair genes ERCC1 and ERCC2, relevant in the neutralization of damage induced by oxaliplatin, and genes encoding enzymes relevant to 5-flurouracil metabolism, [thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD)] in 233 hepatic resection samples. mRNA expression was correlated with a histopathological injury scored via previously validated methods in relation to steatosis, steatohepatitis and sinusoidal obstruction syndrome.
RESULTS: Low-level DPD mRNA expression was associated with steatosis [odds ratio (OR) = 3.95, 95% confidence interval (CI) = 1.53-10.19, P < 0.003], especially when stratified by just those patients exposed to chemotherapy (OR = 4.48, 95% CI = 1.31-15.30 P < 0.02). Low expression of ERCC2 was associated with sinusoidal injury (P < 0.001). There were no further associations between injury patterns and target genes investigated.
CONCLUSIONS: Predisposition to the development of CIHI may be predictable based upon individual patient expression of genes encoding enzymes related to the metabolism of chemotherapeutics.
© 2011 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21999595      PMCID: PMC3238016          DOI: 10.1111/j.1477-2574.2011.00365.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  29 in total

1.  Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease.

Authors:  Michel Henry Mendler; Gary Kanel; Sugantha Govindarajan
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

Review 2.  Genetic factors influencing pyrimidine-antagonist chemotherapy.

Authors:  J G Maring; H J M Groen; F M Wachters; D R A Uges; E G E de Vries
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

3.  Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.

Authors:  Felix G Fernandez; John Ritter; J Wendell Goodwin; David C Linehan; William G Hawkins; Steven M Strasberg
Journal:  J Am Coll Surg       Date:  2005-06       Impact factor: 6.113

4.  Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.

Authors:  André B P van Kuilenburg; Rutger Meinsma; Bernard A Zonnenberg; Lida Zoetekouw; Frank Baas; Koichi Matsuda; Nanaya Tamaki; Albert H van Gennip
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

Review 5.  Nonalcoholic fatty liver disease (NAFLD): a comprehensive review.

Authors:  William B Salt
Journal:  J Insur Med       Date:  2004

Review 6.  Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

Authors:  André B P van Kuilenburg
Journal:  Eur J Cancer       Date:  2004-05       Impact factor: 9.162

Review 7.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.

Authors:  Sanjay Popat; Athena Matakidou; Richard S Houlston
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

8.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Authors:  L Rubbia-Brandt; V Audard; P Sartoretti; A D Roth; C Brezault; M Le Charpentier; B Dousset; P Morel; O Soubrane; S Chaussade; G Mentha; B Terris
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

9.  High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.

Authors:  André B Van Kuilenburg; Rutger Meinsma; Lida Zoetekouw; Albert H Van Gennip
Journal:  Pharmacogenetics       Date:  2002-10

10.  Hepatic steatosis as a potential risk factor for major hepatic resection.

Authors:  K E Behrns; G G Tsiotos; N F DeSouza; M K Krishna; J Ludwig; D M Nagorney
Journal:  J Gastrointest Surg       Date:  1998 May-Jun       Impact factor: 3.267

View more
  7 in total

Review 1.  Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease.

Authors:  Liane Rabinowich; Oren Shibolet
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

2.  The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.

Authors:  S M Robinson; D A Mann; D M Manas; F Oakley; J Mann; S A White
Journal:  Br J Cancer       Date:  2013-10-10       Impact factor: 7.640

3.  Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice.

Authors:  Judith Sommer; Abdo Mahli; Kim Freese; Tobias S Schiergens; Fulya Suzan Kuecuekoktay; Andreas Teufel; Wolfgang E Thasler; Martina Müller; Anja K Bosserhoff; Claus Hellerbrand
Journal:  Oncotarget       Date:  2017-02-21

4.  Global Proteome Changes in Liver Tissue 6 Weeks after FOLFOX Treatment of Colorectal Cancer Liver Metastases.

Authors:  Jozef Urdzik; Anna Vildhede; Jacek R Wiśniewski; Frans Duraj; Ulf Haglund; Per Artursson; Agneta Norén
Journal:  Proteomes       Date:  2016-10-14

5.  Uncovering the roles of dihydropyrimidine dehydrogenase in fatty-acid induced steatosis using human cellular models.

Authors:  Kelly E Sullivan; Sheetal Kumar; Xin Liu; Ye Zhang; Emily de Koning; Yanfei Li; Jing Yuan; Fan Fan
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

6.  An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.

Authors:  Stuart M Robinson; Jelena Mann; Derek M Manas; Derek A Mann; Steven A White
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

Review 7.  Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update.

Authors:  Laura Giuseppina Di Pasqua; Marta Cagna; Clarissa Berardo; Mariapia Vairetti; Andrea Ferrigno
Journal:  Biomedicines       Date:  2022-01-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.